Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 41

1.

Antenatal syphilis screening using point-of-care testing in low- and middle-income countries in Asia and latin america: a cost-effectiveness analysis.

Kuznik A, Muhumuza C, Komakech H, Marques EM, Lamorde M.

PLoS One. 2015 May 26;10(5):e0127379. doi: 10.1371/journal.pone.0127379. eCollection 2015.

2.

Cost-effectiveness of antivenoms for snakebite envenoming in Nigeria.

Habib AG, Lamorde M, Dalhat MM, Habib ZG, Kuznik A.

PLoS Negl Trop Dis. 2015 Jan 8;9(1):e3381. doi: 10.1371/journal.pntd.0003381. eCollection 2015 Jan.

3.

Comparison of costs and discharge outcomes for patients hospitalized for ischemic or hemorrhagic stroke with or without atrial fibrillation in the United States.

Pan X, Simon TA, Hamilton M, Kuznik A.

J Thromb Thrombolysis. 2015 May;39(4):508-15. doi: 10.1007/s11239-014-1144-8.

4.

Burden of disease from atrial fibrillation in adults from seven countries in Latin America.

Cubillos L, Haddad A, Kuznik A, Mould-Quevedo J.

Int J Gen Med. 2014 Sep 2;7:441-8. doi: 10.2147/IJGM.S62819. eCollection 2014.

5.

1-(N-acylamino)alkyl sulfones from N-acyl-α-amino acids or N-alkylamides.

Adamek J, Mazurkiewicz R, Październiok-Holewa A, Grymel M, Kuźnik A, Zielińska K.

J Org Chem. 2014 Mar 21;79(6):2765-70. doi: 10.1021/jo500174a. Epub 2014 Mar 10.

PMID:
24575944
6.

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.

Dorian P, Kongnakorn T, Phatak H, Rublee DA, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Lip GY.

Eur Heart J. 2014 Jul 21;35(28):1897-906. doi: 10.1093/eurheartj/ehu006. Epub 2014 Feb 9.

7.

Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.

Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P.

Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6.

8.

Moving branded statins to lowest copay tier improves patient adherence.

Chen SY, Shah SN, Lee YC, Boulanger L, Mardekian J, Kuznik A.

J Manag Care Pharm. 2014 Jan;20(1):34-42.

9.

Antenatal syphilis screening using point-of-care testing in Sub-Saharan African countries: a cost-effectiveness analysis.

Kuznik A, Lamorde M, Nyabigambo A, Manabe YC.

PLoS Med. 2013 Nov;10(11):e1001545. doi: 10.1371/journal.pmed.1001545. Epub 2013 Nov 5.

10.

Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial.

Goswami NJ, Dekoven M, Kuznik A, Mardekian J, Krukas MR, Liu LZ, Bailey P, Deitrick C, Vincent J.

Int J Gen Med. 2013 Jul 30;6:647-55. doi: 10.2147/IJGM.S47518. Print 2013.

12.

Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin.

Jacobson TA, Wertz DA, Kuznik A, Cziraky M.

Curr Med Res Opin. 2013 Jul;29(7):773-81. doi: 10.1185/03007995.2013.802229. Epub 2013 May 23.

PMID:
23647370
13.

The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment.

Grabowski DC, Lakdawalla DN, Goldman DP, Eber M, Liu LZ, Abdelgawad T, Kuznik A, Chernew ME, Philipson T.

Health Aff (Millwood). 2012 Oct;31(10):2276-85. doi: 10.1377/hlthaff.2011.1120.

PMID:
23048109
14.

Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda.

Sempa J, Ssennono M, Kuznik A, Lamorde M, Sowinski S, Semeere A, Hermans S, Castelnuovo B, Manabe YC.

BMC Public Health. 2012 Sep 4;12:736. doi: 10.1186/1471-2458-12-736.

15.

Evaluating the cost-effectiveness of combination antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Uganda.

Kuznik A, Lamorde M, Hermans S, Castelnuovo B, Auerbach B, Semeere A, Sempa J, Ssennono M, Ssewankambo F, Manabe YC.

Bull World Health Organ. 2012 Aug 1;90(8):595-603. doi: 10.2471/BLT.11.095430.

16.

Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysis.

Manabe YC, Hermans SM, Lamorde M, Castelnuovo B, Mullins CD, Kuznik A.

PLoS One. 2012;7(6):e39187. doi: 10.1371/journal.pone.0039187. Epub 2012 Jun 18.

17.

Medical male circumcision for HIV/AIDS prevention in Uganda - the cost of disposable versus re-usable circumcision kits.

Kuznik A, Lamorde M, Sekavuga DB, Picho B, Coutinho A.

Trop Doct. 2012 Jan;42(1):5-7. doi: 10.1258/td.2011.110297. Epub 2012 Jan 5.

PMID:
22223725
18.

A phase 3 trial of bevacizumab in ovarian cancer.

Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators.

N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. Erratum in: N Engl J Med. 2012 Jan 19;366(3):284.

19.

Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.

Swindle JP, Potash J, Kulakodlu M, Kuznik A, Buikema A.

Am J Geriatr Pharmacother. 2011 Dec;9(6):471-82. doi: 10.1016/j.amjopharm.2011.09.004. Epub 2011 Oct 21.

PMID:
22019005
20.

The value of atorvastatin over the product life cycle in the United States.

Grabner M, Johnson W, Abdulhalim AM, Kuznik A, Mullins CD.

Clin Ther. 2011 Oct;33(10):1433-43. doi: 10.1016/j.clinthera.2011.08.014. Epub 2011 Sep 28.

PMID:
21955936
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk